Update on bb2121 CAR T-cell product for MM from EHA 2018

Update on bb2121 CAR T-cell product for MM from EHA 2018

User Photo
VJHemOnc

2 years
91 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Speaking from the 23rd congress of the European Hematology Association (EHA) 2018 press briefing, held in Stockholm, Sweden, Dr Jesús Berdeja of the Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, gives an update on bb2121, a promising therapy for patients with heavily pre-treated relapsed/refractory multiple myeloma (MM).
Up Next Autoplay
>